Monica Ronzoni
Overview
Explore the profile of Monica Ronzoni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
1461
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
De Nardi P, Mistrangelo M, Burtulo G, Passoni P, Slim N, Ronzoni M, et al.
J Surg Oncol
. 2020 Sep;
123(1):315-321.
PMID: 32964456
Background And Objectives: The aim of our study was to analyze the results of selective inguinal node irradiation in patients with anal cancer, based on the biopsy of the inguinal...
12.
Slim N, Passoni P, Incerti E, Tummineri R, Gumina C, Cattaneo G, et al.
Sci Rep
. 2020 Sep;
10(1):14613.
PMID: 32884036
To assess the role of sentinel lymph-node biopsy (SLNB) and FDG-PET in staging and radiation treatment (RT) of anal cancer patients. This retrospective study was performed on 80 patients (male:...
13.
Broggi S, Passoni P, Gumina C, Palmisano A, Bresolin A, Burgio V, et al.
Radiother Oncol
. 2020 May;
149:174-180.
PMID: 32417346
Background And Purpose: A previously introduced index based on early tumor (GTV) regression (ERI) during neo-adjuvant radio-chemotherapy of rectal cancer was used to investigate the impact of changes of oxaliplatin...
14.
Cremolini C, Antoniotti C, Rossini D, Lonardi S, Loupakis F, Pietrantonio F, et al.
Lancet Oncol
. 2020 Mar;
21(4):497-507.
PMID: 32164906
Background: The triplet FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab showed improved outcomes for patients with metastatic colorectal cancer, compared with FOLFIRI (fluorouracil, leucovorin, and irinotecan) plus bevacizumab. However,...
15.
Petrelli F, Labianca R, Zaniboni A, Lonardi S, Galli F, Rulli E, et al.
JAMA Oncol
. 2020 Feb;
6(4):547-551.
PMID: 32053133
Importance: The addition of oxaliplatin to the standard 6-month fluorouracil-based adjuvant chemotherapy in stage II colorectal cancer has been reported to reduce the risk of relapse although it does not...
16.
Ruzzo A, Graziano F, Galli F, Galli F, Rulli E, Lonardi S, et al.
Sci Rep
. 2020 Feb;
10(1):1918.
PMID: 32005869
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
17.
Rosati G, Galli F, Cantore M, Bergamo F, Banzi M, Giulia Zampino M, et al.
Oncologist
. 2020 Jan;
25(6):e928-e935.
PMID: 31943506
Background: Although American Society of Clinical Oncology and European Society for Medical Oncology guidelines have identified the negative prognostic factors that clinicians have to consider when treating their patients with...
18.
De Nardi P, Salandini M, Chiari D, Pecorelli N, Cristel G, Damascelli A, et al.
Curr Probl Cancer
. 2019 Nov;
44(2):100510.
PMID: 31703987
Aim: To establish the correlation between changes in body composition after neoadjuvant chemoradiotherapy (nCRT) and postoperative outcomes, in patients with advanced low rectal cancer. Methods: Patients with clinical stage T≥3...
19.
Ruzzo A, Graziano F, Galli F, Galli F, Rulli E, Lonardi S, et al.
Sci Rep
. 2019 Aug;
9(1):11527.
PMID: 31395900
Polymorphisms contribute to inter-individual differences and show a promising predictive role for chemotherapy-related toxicity in colon cancer (CC). TOSCA is a multicentre, randomized, non-inferiority, phase III study conducted in high-risk...
20.
Galbiati S, Damin F, Ferraro L, Soriani N, Burgio V, Ronzoni M, et al.
Cells
. 2019 Jul;
8(8).
PMID: 31344983
It has now been established that in biological fluids such as blood, it is possible to detect cancer causing genomic alterations by analysing circulating tumour DNA (ctDNA). Information derived from...